Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
10.63
+0.03 (0.28%)
At close: Jun 18, 2025, 4:00 PM
10.62
-0.01 (-0.09%)
After-hours: Jun 18, 2025, 4:04 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Theravance Biopharma stock have a consensus rating of "Buy" and an average price target of $14.5, which forecasts a 36.41% increase in the stock price over the next year. The lowest target is $9 and the highest is $24.
Price Target: $14.5 (+36.41%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +125.78% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +41.11% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +41.11% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +41.11% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +41.11% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
92.41M
from 64.38M
Increased by 43.53%
Revenue Next Year
81.55M
from 92.41M
Decreased by -11.75%
EPS This Year
-0.34
from -1.15
EPS Next Year
-1.03
from -0.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.9M | 90.0M | 134.8M | ||
| Avg | 92.4M | 81.6M | 109.4M | ||
| Low | 75.4M | 67.9M | 76.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.2% | -2.6% | 65.3% | ||
| Avg | 43.5% | -11.7% | 34.1% | ||
| Low | 17.1% | -26.5% | -6.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | -0.86 | -0.05 | ||
| Avg | -0.34 | -1.03 | -0.35 | ||
| Low | -0.48 | -1.31 | -0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.